Shares of Haemonetics Corp. (NYSE:HAE) have been given a consensus rating of “Hold” by the ten research firms that are covering the firm. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and one has assigned a buy rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $35.00.

HAE has been the subject of a number of recent analyst reports. Jefferies Group lifted their target price on shares of Haemonetics Corp. from $32.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday, August 2nd. Benchmark Co. lifted their target price on shares of Haemonetics Corp. from $28.00 to $32.00 and gave the stock a “hold” rating in a research note on Tuesday, August 2nd. Barrington Research cut shares of Haemonetics Corp. from an “outperform” rating to a “market perform” rating in a research note on Wednesday, August 3rd. Zacks Investment Research upgraded shares of Haemonetics Corp. from a “strong sell” rating to a “hold” rating in a research note on Monday, July 4th. Finally, Sidoti cut shares of Haemonetics Corp. from a “buy” rating to a “neutral” rating and set a $39.00 target price for the company. in a research note on Monday, August 15th.

In other news, CEO Christopher Simon bought 60,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 4th. The stock was purchased at an average cost of $35.00 per share, for a total transaction of $2,100,000.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Ronald Merriman sold 4,337 shares of the business’s stock in a transaction on Wednesday, August 17th. The shares were sold at an average price of $35.14, for a total transaction of $152,402.18. Following the completion of the transaction, the director now owns 22,088 shares of the company’s stock, valued at $776,172.32. The disclosure for this sale can be found here. 1.50% of the stock is currently owned by corporate insiders.

Several institutional investors have recently bought and sold shares of the stock. BlackRock Inc. boosted its position in Haemonetics Corp. by 125.7% in the first quarter. BlackRock Inc. now owns 3,501 shares of the company’s stock valued at $122,000 after buying an additional 1,950 shares in the last quarter. Tower Research Capital LLC TRC purchased a new position in Haemonetics Corp. during the second quarter valued at about $133,000. Invictus RG boosted its position in Haemonetics Corp. by 20.1% in the first quarter. Invictus RG now owns 4,074 shares of the company’s stock valued at $143,000 after buying an additional 681 shares in the last quarter. PineBridge Investments L.P. boosted its position in Haemonetics Corp. by 4.2% in the second quarter. PineBridge Investments L.P. now owns 6,473 shares of the company’s stock valued at $187,000 after buying an additional 261 shares in the last quarter. Finally, Teacher Retirement System of Texas boosted its position in Haemonetics Corp. by 13.9% in the second quarter. Teacher Retirement System of Texas now owns 7,081 shares of the company’s stock valued at $205,000 after buying an additional 865 shares in the last quarter. Hedge funds and other institutional investors own 98.78% of the company’s stock.

Shares of Haemonetics Corp. (NYSE:HAE) opened at 37.39 on Tuesday. The stock has a 50 day moving average of $35.41 and a 200-day moving average of $32.06. Haemonetics Corp. has a 52 week low of $25.98 and a 52 week high of $37.99. The stock’s market capitalization is $1.92 billion.

Haemonetics Corp. (NYSE:HAE) last released its earnings results on Monday, August 1st. The company reported $0.25 EPS for the quarter, missing analysts’ consensus estimates of $0.28 by $0.03. The company earned $210 million during the quarter, compared to analyst estimates of $205.41 million. Haemonetics Corp. had a positive return on equity of 10.75% and a negative net margin of 7.25%. The firm’s revenue for the quarter was down 1.6% on a year-over-year basis. During the same quarter last year, the business earned $0.35 earnings per share. On average, equities research analysts expect that Haemonetics Corp. will post $1.44 EPS for the current year.

Haemonetics Corp. Company Profile

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

5 Day Chart for NYSE:HAE

Receive News & Ratings for Haemonetics Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.